Home / Business and Economy / InnoCare Pharma Seals $3.35B Deal with Eli Lilly
InnoCare Pharma Seals $3.35B Deal with Eli Lilly
24 Sep
Summary
- InnoCare Pharma and Eli Lilly entered a collaboration agreement.
- The deal could potentially be worth up to $3.35 billion.
- The agreement involves research collaboration and licensing.
On September 24, 2026, InnoCare Pharma, a Chinese pharmaceutical company, revealed a significant development in its operations. The company has entered into a research collaboration and license agreement with the global pharmaceutical leader, Eli Lilly.
This strategic alliance is poised to be highly lucrative, with the potential to generate up to approximately $3.35 billion for InnoCare Pharma. The agreement encompasses joint research efforts and licensing of intellectual property, underscoring a shared commitment to advancing pharmaceutical innovation.
Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
